Five Prime Therapeutics (FPRX) Tops Q2 EPS by 30c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Five Prime Therapeutics Announces Second Quarter 2018 Financial Results
August 8, 2018 4:05 PM EDTCabiralizumab continues to advance in randomized Phase 2 trial in pancreatic cancer Bemarituzumab has advanced through Phase 1 safety lead-in of Phase 1/3 FIGHT global trial in gastric cancer; preparation for Phase 3 portion underway Four product candidates in the clinic, fifth planned by end of 2018
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Five Prime Therapeutics, Inc. (NASDAQ:... More
